Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides and uses thereof

US10377806B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Paul E. Morin · Pennington, US
• Daniel Cohen · Watertown, US
• Ranjan Mukherjee · East Lansing, US
• Timothy P. Reilly · New Hope, US
• Rose C. Christian · Lawrenceville, US
• Dasa Lipovsek · Pepperell, US
• Ray Camphausen · Wayland, US
• John Krupinski · Flemington, US

Key dates

• Filing date: May 15, 2018
• Grant date: Aug 13, 2019
• Expiry date: May 15, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.